Related Experiment Video

Updated: Jun 4, 2026

Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
10:32

Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model

Published on: April 2, 2021

Erythropoietin and retinopathy of prematurity

C Romagnoli1, M G Tesfagabir, C Giannantonio

  • 1Division of Neonatology, Department of Paediatrics, Catholic University of Rome, Italy. j.rampazzi@emec-roma.com

Early Human Development
|February 10, 2011
PubMed

Insights

Erythropoietin (EPO) may increase the risk of Retinopathy of Prematurity (ROP) in newborn infants, depending on treatment timing and dosage. Further research is needed to clarify this complex relationship.

Area of Science:

  • Neonatal Medicine
  • Ophthalmology
  • Biochemistry

Background:

  • Erythropoietin (EPO) is a glycoprotein vital for red blood cell production, with known angiogenic and neuroprotective roles in neonates.
  • Retinopathy of Prematurity (ROP) is a significant cause of visual impairment in preterm infants, involving hypoxia-driven angiogenic factors.
  • Existing studies on EPO's hematopoietic effects suggest a link to ROP risk, but findings are conflicting regarding timing and dosage.

Purpose of the Study:

  • To review the current understanding of the relationship between Erythropoietin (EPO) administration and the risk of Retinopathy of Prematurity (ROP) in newborn infants.
  • To highlight the inconsistencies in existing research and the need for specifically designed studies.
  • To emphasize the importance of considering EPO's neuroprotective role in future research concerning ROP.

Main Methods:

  • Review of existing literature on Erythropoietin (EPO) and its effects in neonatal populations.
  • Analysis of studies examining the correlation between EPO treatment (timing and dosage) and the incidence of Retinopathy of Prematurity (ROP).
  • Consideration of EPO's dual roles: hematopoietic and potential neuroprotective effects.

Main Results:

  • Early observations suggested EPO treatment might elevate ROP risk.
  • More recent reports indicate that late, high-dose recombinant human EPO (rhEPO) may also increase ROP risk.
  • Current studies were not specifically designed to definitively establish a causal link between EPO and ROP.

Conclusions:

  • The precise relationship between EPO and ROP remains unclear due to limitations in existing study designs.
  • Further well-designed research is essential to elucidate the impact of EPO on ROP development.
  • Cautious use of EPO in neonates, particularly very low birth weight infants, is recommended pending further evidence.

More Related Videos

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents09:28

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina07:32

Assessment of Vascular Regeneration in the CNS Using the Mouse Retina

Published on: June 23, 2014

Related Concept Videos

Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...